Article
Chronic Kidney Disease: A Benefit-Risk Panorama of Baricitinib through Integrating Network Toxicology, Molecular Docking and Real-World Evidence
2025-09-10
Abstract excerpt
<title>Abstract</title> <p>Background Chronic kidney disease (CKD) poses substantial global morbidity and mortality burdens, yet current therapeutic strategies fail to halt or reverse renal fibrosis. Baricitinib, a selective JAK1/JAK2 inhibitor, demonstrates dual anti-inflammatory and anti-fibrotic properties in autoimmune conditions; however, its comprehensive therapeutic utility and safety constraints in CKD re...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- d4429360-7dd8-528f-94a7-4bfe72fe0c47
- DOI
- 10.21203/rs.3.rs-7498649/v1
